Eoin Martyn - Taylor Wessing

Eoin specialises in patents with a particular focus on advising pharmaceutical and biotechnology companies in relation to patent infringement and validity issues.

Eoin has extensive experience in cross-border patent litigation related to blockbuster pharmaceutical drugs representing IP owners, licensees, as well as generic and biosimilar manufacturers. With extensive international experience, Eoin has operated across numerous major jurisdictions.

Eoin is a Authorised Representative before the Unified Patent Court (UPC).

Eoin’s expertise extends to the life cycle management of medicinal products, regulatory advice, and advising on European data and marketing exclusivity.

Eoin has advised a diverse range of clients, especially within the life sciences, technology and telecommunications sectors, on matters concerning the acquisition and licensing of intellectual property rights.

CV

Since 2024 Partner, Taylor Wessing

2021 - 2024 Senior Associate, McCann FitzGerald LLP

2017 - 2021 Senior Associate, Ashurst. Sydney, Australia

Carrière

Since 2024 Partner, Taylor Wessing

2021 - 2024 Senior Associate, McCann FitzGerald LLP

2017 - 2021 Senior Associate, Ashurst. Sydney, Australia

Formation

2018 Admitted as a lawyer, High Court of Australia and as a legal practitioner in Queensland, Australia

2015 Admission as a Solicitor, England and Wales, Ireland

2014 Legal Practice Certificate, BPP University, London

Prix et distinctions

Legal 500 Ireland 2024

Featured

Legal 500 Ireland 2023

Managing Intellectual Property Ireland 2021-2023

Actualités et publications récentes

View Eoin's insights

Cliquer ici pour en savoir plus

République d'Irlande

Ireland – deals of 2024

14 janvier 2025

par plusieurs auteurs

Brevets et innovation

A look at the Unified Patent Court's first year of operation and what lies ahead

25 juin 2024

par plusieurs auteurs

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Court of Appeal in Ireland grants interlocutory injunction restraining the launch of Teva’s generic apixaban product pending determination of appeal

14 juin 2024

Briefing

par Eoin Martyn

Cliquer ici pour en savoir plus